The only FDA-approved cannabis-derived drug is for epilepsy. CBD reduces seizures by up to 50%.
Epidiolex — a purified CBD oral solution — is the first FDA-approved cannabis-derived medication, approved for Dravet syndrome and Lennox-Gastaut syndrome. Clinical trials showed 39–50% reductions in seizure frequency.
Medical Disclaimer: This information is for educational purposes only. Consult a qualified healthcare provider before using cannabis for Epilepsy & Seizures. Find a cannabis-knowledgeable provider →
Epilepsy affects 3.4 million Americans and is characterized by recurrent seizures caused by abnormal electrical activity in the brain. Approximately 30% of epilepsy patients have drug-resistant epilepsy — their seizures do not respond to available medications.
CBD's anticonvulsant properties were first widely publicized through the story of Charlotte Figi, a child with Dravet syndrome whose severe seizures were dramatically reduced by a high-CBD cannabis extract. This case catalyzed the modern medical cannabis movement and ultimately led to FDA approval of Epidiolex in 2018.
Epidiolex (purified CBD) is the first and only FDA-approved cannabis-derived medication. Clinical trials demonstrated 39% reduction in seizures for Lennox-Gastaut syndrome and 50% reduction for Dravet syndrome compared to placebo — remarkable results for conditions that are notoriously treatment-resistant.
The mechanism of CBD's anticonvulsant action is not fully understood but involves multiple pathways: modulation of sodium and calcium channels, enhancement of GABA inhibitory signaling, and reduction of neuroinflammation. Notably, CBD's anticonvulsant effects appear to be independent of CB1 receptor activation.
CBD modulates multiple ion channels (sodium, calcium, potassium) involved in neuronal excitability. It enhances GABA-mediated inhibitory signaling and reduces glutamate excitatory activity. CBD also reduces neuroinflammation through TRPV1 and GPR55 receptor modulation. These mechanisms are distinct from most antiepileptic drugs, making CBD effective in drug-resistant cases.
Our editorial team has tested hundreds of cannabis products for epilepsy & seizures management. These brands consistently deliver the highest quality formulations with transparent lab testing.
World-leading scientist formulation. Standardized full spectrum profiles, not just a CBD count. Pioneered the cannabis topical liniment spray.
Liniment spray is the most effective topical staff have tested.
Best For
Same world-leading scientist as CBDWellness. Verified THC non-detect on every batch by ISO 17025 accredited lab — trusted by military, athletes, and law enforcement.
The only broad spectrum brand staff trust for drug-tested professionals.
Best For
Same world-leading scientist as CBDWellness. Standardized THC formulations for consistent, reliable therapeutic effects. Available at licensed dispensaries.
THC topical liniment spray is the most effective cannabis topical staff have tested.
Best For
Editorial Disclosure: These brands are selected by our editorial team based on independent staff testing, lab result analysis, and 7 years of annual awards data. We do not accept payment for editorial placement. See our Annual Awards methodology for full details.